Evidence map›Paper›PMID 37058173›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.

Béranger Lueza, Anne Aupérin, Charlotte Rigaud, Thomas G Gross, Marta Pillon, Rafael F Delgado, Anne Uyttebroeck, G A Amos Burke, József Zsíros, Monika Csóka and 4 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01516580 (Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01516580 phase3completednot on this map

Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2011 to 2022Enrolled482ConditionsB-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-typeArmsVincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C, Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 8 countries.

Béranger LuezaService de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94805, Villejuif Cedex, France.
Anne AupérinService de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94805, Villejuif Cedex, France.
Charlotte RigaudDépartement de Cancérologie de l'Enfant et l'adolescent, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
Thomas G GrossDepartment of Pediatrics, Center for Cancer and Blood Diseases, Children's Hospital Colorado, Aurora, CO, USA.
Marta PillonPediatric Hematology and Oncology, University of Padova, Padua, Italy.
Rafael F DelgadoPediatric Hematology and Oncology, University of Valencia, Valencia, Spain.
Anne UyttebroeckDepartment of Pediatric Hematology and Oncology, University Hospitals Leuven, Louvain, Belgium.
G A Amos BurkeDepartment of Paediatric Haematology, Oncology and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0003-2671-9972
József ZsírosPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Monika Csóka2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Mathieu SimoninDepartment of Pediatric Oncology and Hematology, Armand Trousseau Hospital-APHP, Sorbonne University, Paris, France.
Catherine PatteDépartement de Cancérologie de l'Enfant et l'adolescent, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
Véronique Minard-ColinDépartement de Cancérologie de l'Enfant et l'adolescent, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
Julia BonastreService de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94805, Villejuif Cedex, France. julia.bonastre@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-9884-0072
Inserm · FRUniversité Paris-Saclay · FRCambridge University Hospitals NHS Foundation Trust · GBChildren's Hospital Colorado · USKU Leuven · BEPrincess Máxima Center · NLSemmelweis University · HUSorbonne Université · FRUniversitat de València · ESUniversity of Padua · IT

Funding

Cancer Research UK 13336
6 · The paper itself

Abstract

objectivesThe randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin's lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting.

methodsWe used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (n = 328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome.

resultsOS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference € - 3 710 [95% CI € - 17,877; € 10,525] in favor of rituximab-chemotherapy group. For a € 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings.

conclusionAdding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France.

trial registrationClinicalTrials.gov identifier: NCT01516580.

Indexed as

Cost-Effectiveness AnalysisLymphoma, Non-HodgkinAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildCost-Benefit AnalysisHumansProgression-Free SurvivalRituximabRituximabEconomic evaluationHigh-risk B-NHLImmunotherapySemi-Markov model

Identifiers

PMID37058173
PMCPMC10858928
OpenAlexW4365482978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.